DGIdb - BELINOSTAT Drug Record

BELINOSTAT chembl:CHEMBL408513 ApprovedAntineoplasticImmunotherapy

Alternate Names:

PXD-101
PX-105684
NSC726630
BELINOSTAT
BELEODAQ
rxcui:1543543
chembl:CHEMBL408513
pubchem.compound:6918638
chemidplus:866323-14-0
drugbank:05015

Drug Info:

FDA Approval	Peripheral T-cell lymphoma
Drug Class	Small molecule inhibitor
FDA Approval	not approved
Drug Class	Small molecule
Drug Indications	antineoplastic agent
Drug Categories	cytochrome p-450 cyp1a2 inducers
Drug Categories	cytochrome p-450 cyp1a2 inducers (weak)
Drug Categories	cytochrome p-450 cyp2a6 substrates
Drug Categories	cytochrome p-450 cyp2a6 substrates with a narrow therapeutic index
Drug Categories	cytochrome p-450 cyp2c8 inhibitors
Drug Categories	cytochrome p-450 cyp2c8 inhibitors (weak)
Drug Categories	cytochrome p-450 cyp2c9 inhibitors
Drug Categories	cytochrome p-450 cyp2c9 inhibitors (strength unknown)
Drug Categories	cytochrome p-450 cyp2c9 substrates
Drug Categories	cytochrome p-450 cyp2c9 substrates with a narrow therapeutic index
Drug Categories	cytochrome p-450 cyp3a substrates
Drug Categories	cytochrome p-450 cyp3a4 substrates
Drug Categories	cytochrome p-450 cyp3a4 substrates with a narrow therapeutic index
Drug Categories	cytochrome p-450 enzyme inducers
Drug Categories	cytochrome p-450 enzyme inhibitors
Drug Categories	cytochrome p-450 substrates
Drug Categories	immunosuppressive agents
Drug Categories	p-glycoprotein substrates
Drug Categories	ugt1a1 substrates
Drug Categories	ugt1a1 substrates with narrow therapeutic index

(8 More Sources)

Publications:

Kozlov MV et al., 2015, Pyridine hydroxamic acids are specific anti-HCV agents affecting HDAC6., Bioorg Med Chem Lett
Hood K et al., 2016, Belinostat for Relapsed or Refractory Peripheral T-Cell Lymphoma., J Adv Pract Oncol
Goey et al., 2016, Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancer., J Clin Pharmacol
Perruchoud et al., 1978, [Spirometry, respiratory mechanics and pulmonary gas exchange in pulmonary emphysema]., Wien Med Wochenschr
Stumpel et al., 2012, Connectivity mapping identifies HDAC inhibitors for the treatment of t(4;11)-positive infant acute lymphoblastic leukemia., Leukemia
Cechová et al., 1978, [Asymmetry and symmetry of caries in the Czech population in the past]., Cesk Stomatol
He et al., 2013, Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma., Cancer Discov

BELINOSTAT FBXW7

Interaction Score: 1.01

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type hematologic cancer

Response Type sensitive

Approval Status Preclinical

PMIDs:
23274910

Sources:
JAX-CKB
BELINOSTAT HDAC7

Interaction Score: 0.77

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Specific Action of the Ligand Inhibition

Endogenous Drug? False

PMIDs:
25937017

Sources:
DTC TdgClinicalTrial TALC MyCancerGenome GuideToPharmacology ChemblInteractions
BELINOSTAT HDAC9

Interaction Score: 0.72

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Trial Name PXD101

Novel drug target Established target

PMIDs:
25937017

Sources:
DTC TdgClinicalTrial TALC MyCancerGenome GuideToPharmacology
BELINOSTAT HDAC1

Interaction Score: 0.69

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name PXD101

Novel drug target Established target

Notes

PMIDs:
25937017 28090369

Sources:
DTC TdgClinicalTrial DrugBank TALC MyCancerGenome GuideToPharmacology ChemblInteractions
BELINOSTAT HDAC4

Interaction Score: 0.68

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name PXD101

Notes

PMIDs:
25937017

Sources:
DTC TdgClinicalTrial TALC MyCancerGenome GuideToPharmacology ChemblInteractions
BELINOSTAT HDAC5

Interaction Score: 0.64

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Inhibition

PMIDs:
25937017

Sources:
DTC TdgClinicalTrial TALC GuideToPharmacology ChemblInteractions
BELINOSTAT HDAC10

Interaction Score: 0.58

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name PXD101

Novel drug target Established target

Direct Interaction yes

PMIDs:
25937017

Sources:
DTC TdgClinicalTrial TALC ChemblInteractions
BELINOSTAT HDAC3

Interaction Score: 0.58

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Histone deacetylase inhibitor

Direct Interaction yes

Specific Action of the Ligand Inhibition

PMIDs:
25937017

Sources:
DTC TdgClinicalTrial TALC GuideToPharmacology ChemblInteractions
BELINOSTAT HDAC6

Interaction Score: 0.55

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Mechanism of Interaction Histone deacetylase inhibitor

Direct Interaction yes

PMIDs:
25937017

Sources:
DTC TdgClinicalTrial TALC GuideToPharmacology ChemblInteractions
BELINOSTAT HDAC11

Interaction Score: 0.52

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Histone deacetylase inhibitor

Trial Name PXD101

PMIDs:
25937017

Sources:
DTC TdgClinicalTrial ChemblInteractions
BELINOSTAT HDAC8

Interaction Score: 0.51

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Specific Action of the Ligand Inhibition

Endogenous Drug? False

PMIDs:
25937017

Sources:
DTC TdgClinicalTrial TALC GuideToPharmacology ChemblInteractions
BELINOSTAT HDAC2

Interaction Score: 0.46

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Endogenous Drug? False

Specific Action of the Ligand Inhibition

PMIDs:
25937017

Sources:
DTC TdgClinicalTrial TALC GuideToPharmacology ChemblInteractions
BELINOSTAT UGT1A1

Interaction Score: 0.31

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26313268

Sources:
FDA CIViC
BELINOSTAT KMT2A

Interaction Score: 0.31

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family HDAC inhibitor

Alteration MLL__.

PMIDs:
351975 22015773 357032

Sources:
CGI

DrugBank: DB05015
- Version: 5.1.7
Alternate Names:

BELINOSTAT DrugBank Drug Name

866323-14-0 CAS Number

Beleodaq Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Groups investigational

Publications:

Hood K et al., 2016, Belinostat for Relapsed or Refractory Peripheral T-Cell Lymphoma., J Adv Pract Oncol
MyCancerGenome: BELINOSTAT
- Version: 20-Jun-2017
Alternate Names:

BELEODAQ Trade Name

Drug Info:

Drug Class Small molecule inhibitor

FDA Approval Peripheral T-cell lymphoma

Publications:
TdgClinicalTrial: BELINOSTAT
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small molecule

FDA Approval not approved

Publications:
DTC: BELINOSTAT
- Version: 02-September-2020
Alternate Names:

CHEMBL408513 ChEMBL Drug ID

Drug Info:

Publications:

Kozlov MV et al., 2015, Pyridine hydroxamic acids are specific anti-HCV agents affecting HDAC6., Bioorg Med Chem Lett
JAX-CKB: Belinostat
- Version: 27-September-2017
Alternate Names:

Drug Info:

Publications:

He et al., 2013, Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma., Cancer Discov

CGI: Belinostat

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Perruchoud et al., 1978, [Spirometry, respiratory mechanics and pulmonary gas exchange in pulmonary emphysema]., Wien Med Wochenschr

Stumpel et al., 2012, Connectivity mapping identifies HDAC inhibitors for the treatment of t(4;11)-positive infant acute lymphoblastic leukemia., Leukemia

Cechová et al., 1978, [Asymmetry and symmetry of caries in the Czech population in the past]., Cesk Stomatol

CIViC: BELINOSTAT

Version: 14-September-2020

Alternate Names:

Drug Info:

Publications:

Goey et al., 2016, Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancer., J Clin Pharmacol

TALC: BELINOSTAT
- Version: 12-May-2016
Alternate Names:

BELINOSTAT Primary Drug Name

BELINOSTAT Drug Generic Name

PXD 101 Drug Synonym

Drug Info:

Publications:
GuideToPharmacology: 187051798
- Version: 29-September-2020
Alternate Names:

BELINOSTAT GuideToPharmacology Ligand Name

Drug Info:

Publications:
ChemblInteractions: CHEMBL408513
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL408513
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
FDA: Belinostat
- Version: 04-September-2020
Alternate Names:

Drug Info:

Publications:

Indication/Tumor Type	hematologic cancer
Response Type	sensitive
Approval Status	Preclinical

Notes
Specific Action of the Ligand	Inhibition
Endogenous Drug?	False

Direct Interaction?	False
Endogenous Drug?	False
Specific Action of the Ligand	Inhibition

Trial Name	PXD101
Novel drug target	Established target
Direct Interaction	yes

Mechanism of Interaction	Histone deacetylase inhibitor
Direct Interaction	yes
Specific Action of the Ligand	Inhibition

BELINOSTAT	DrugBank Drug Name
866323-14-0	CAS Number
Beleodaq	Drug Brand

Drug Type	small molecule
Drug Groups	approved
Drug Groups	investigational

BELINOSTAT	Primary Drug Name
BELINOSTAT	Drug Generic Name
PXD 101	Drug Synonym

Drug family	HDAC inhibitor
Alteration	MLL__.

BELINOSTAT Drug Record

BELINOSTAT chembl:CHEMBL408513 ApprovedAntineoplasticImmunotherapy

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type hematologic cancer Response Type sensitive Approval Status Preclinical

PMIDs: 23274910

Sources: JAX-CKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Specific Action of the Ligand Inhibition Endogenous Drug? False

PMIDs: 25937017

Sources: DTC TdgClinicalTrial TALC MyCancerGenome GuideToPharmacology ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Trial Name PXD101 Novel drug target Established target

PMIDs: 25937017

Sources: DTC TdgClinicalTrial TALC MyCancerGenome GuideToPharmacology

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name PXD101 Novel drug target Established target Notes

PMIDs: 25937017 28090369

Sources: DTC TdgClinicalTrial DrugBank TALC MyCancerGenome GuideToPharmacology ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Novel drug target Established target Trial Name PXD101 Notes

PMIDs: 25937017

Sources: DTC TdgClinicalTrial TALC MyCancerGenome GuideToPharmacology ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction? False Endogenous Drug? False Specific Action of the Ligand Inhibition

PMIDs: 25937017

Sources: DTC TdgClinicalTrial TALC GuideToPharmacology ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name PXD101 Novel drug target Established target Direct Interaction yes

PMIDs: 25937017

Sources: DTC TdgClinicalTrial TALC ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Histone deacetylase inhibitor Direct Interaction yes Specific Action of the Ligand Inhibition

PMIDs: 25937017

Sources: DTC TdgClinicalTrial TALC GuideToPharmacology ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Mechanism of Interaction Histone deacetylase inhibitor Direct Interaction yes

PMIDs: 25937017

Sources: DTC TdgClinicalTrial TALC GuideToPharmacology ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction Histone deacetylase inhibitor Trial Name PXD101

PMIDs: 25937017

Sources: DTC TdgClinicalTrial ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Specific Action of the Ligand Inhibition Endogenous Drug? False

PMIDs: 25937017

Sources: DTC TdgClinicalTrial TALC GuideToPharmacology ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Endogenous Drug? False Specific Action of the Ligand Inhibition

PMIDs: 25937017

Sources: DTC TdgClinicalTrial TALC GuideToPharmacology ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26313268

Sources: FDA CIViC

Interaction Types & Directionality: n/a

Interaction Info: Drug family HDAC inhibitor Alteration MLL__.

PMIDs: 351975 22015773 357032

Sources: CGI

DrugBank: DB05015

Alternate Names: BELINOSTAT DrugBank Drug Name 866323-14-0 CAS Number Beleodaq Drug Brand

Drug Info: Drug Type small molecule Drug Groups approved Drug Groups investigational

Publications: Hood K et al., 2016, Belinostat for Relapsed or Refractory Peripheral T-Cell Lymphoma., J Adv Pract Oncol

MyCancerGenome: BELINOSTAT

Alternate Names: BELEODAQ Trade Name

Drug Info: Drug Class Small molecule inhibitor FDA Approval Peripheral T-cell lymphoma

Publications:

TdgClinicalTrial: BELINOSTAT

Alternate Names:

Drug Info: Drug Indications antineoplastic agent Drug Class Small molecule FDA Approval not approved

Publications:

DTC: BELINOSTAT

Alternate Names: CHEMBL408513 ChEMBL Drug ID

Drug Info:

Publications: Kozlov MV et al., 2015, Pyridine hydroxamic acids are specific anti-HCV agents affecting HDAC6., Bioorg Med Chem Lett

JAX-CKB: Belinostat

Alternate Names:

Drug Info:

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type hematologic cancer

Response Type sensitive

Approval Status Preclinical

PMIDs:
23274910

Sources:
JAX-CKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Specific Action of the Ligand Inhibition

Endogenous Drug? False

PMIDs:
25937017

Sources:
DTC TdgClinicalTrial TALC MyCancerGenome GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Trial Name PXD101

Novel drug target Established target

PMIDs:
25937017

Sources:
DTC TdgClinicalTrial TALC MyCancerGenome GuideToPharmacology

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name PXD101

Novel drug target Established target

Notes

PMIDs:
25937017 28090369

Sources:
DTC TdgClinicalTrial DrugBank TALC MyCancerGenome GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name PXD101

Notes

PMIDs:
25937017

Sources:
DTC TdgClinicalTrial TALC MyCancerGenome GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Inhibition

PMIDs:
25937017

Sources:
DTC TdgClinicalTrial TALC GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name PXD101

Novel drug target Established target

Direct Interaction yes

PMIDs:
25937017

Sources:
DTC TdgClinicalTrial TALC ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Histone deacetylase inhibitor

Direct Interaction yes

Specific Action of the Ligand Inhibition

PMIDs:
25937017

Sources:
DTC TdgClinicalTrial TALC GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Mechanism of Interaction Histone deacetylase inhibitor

Direct Interaction yes

PMIDs:
25937017

Sources:
DTC TdgClinicalTrial TALC GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Histone deacetylase inhibitor

Trial Name PXD101

PMIDs:
25937017

Sources:
DTC TdgClinicalTrial ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Specific Action of the Ligand Inhibition

Endogenous Drug? False

PMIDs:
25937017

Sources:
DTC TdgClinicalTrial TALC GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Endogenous Drug? False

Specific Action of the Ligand Inhibition

PMIDs:
25937017

Sources:
DTC TdgClinicalTrial TALC GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
26313268

Sources:
FDA CIViC

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family HDAC inhibitor

Alteration MLL__.

PMIDs:
351975 22015773 357032

Sources:
CGI

Alternate Names:

BELINOSTAT DrugBank Drug Name

866323-14-0 CAS Number

Beleodaq Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Groups investigational

Publications:

Hood K et al., 2016, Belinostat for Relapsed or Refractory Peripheral T-Cell Lymphoma., J Adv Pract Oncol

Alternate Names:

BELEODAQ Trade Name

Drug Info:

Drug Class Small molecule inhibitor

FDA Approval Peripheral T-cell lymphoma

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small molecule

FDA Approval not approved

Alternate Names:

CHEMBL408513 ChEMBL Drug ID

Publications:

Kozlov MV et al., 2015, Pyridine hydroxamic acids are specific anti-HCV agents affecting HDAC6., Bioorg Med Chem Lett

Publications:

He et al., 2013, Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma., Cancer Discov

Publications:

Goey et al., 2016, Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancer., J Clin Pharmacol

Alternate Names:

BELINOSTAT Primary Drug Name

BELINOSTAT Drug Generic Name

PXD 101 Drug Synonym

Alternate Names:

BELINOSTAT GuideToPharmacology Ligand Name